SCHEMBL3401425

SCHEMBL3401425

CCOC(=O)c1cn(CC)c(-c2cccc3ccccc23)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.50
GABRA2 P47869 5/20 0.49
GABRB2 P47870 5/20 0.49
CYP1A2 P05177 1/20 0.49
GAA P10253 1/20 0.48
MAPT P10636 2/20 0.47
CDC25B P30305 2/20 0.47
FNTA P49354 1/20 0.47
FNTB P49356 1/20 0.47
ALDH1A1 P00352 1/20 0.45
HSD17B10 Q99714 1/20 0.45
RAB9A P51151 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MAPK1 P28482 2/20 0.44
HCRTR1 O43613 1/20 0.44
TP53 P04637 1/20 0.44
ALOX15 P16050 1/20 0.44
CDC25A P30304 1/20 0.44
CDC25C P30307 1/20 0.44
KDM4E B2RXH2 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3401606 0.86 KDM4E (0.46) TDP1ALDH1A1KDM4EKMT2A
SCHEMBL3399942 0.75 HTR2C (0.42) LMNA
SCHEMBL3400011 0.75 ALDH1A1 (0.50) GAAMAPTCDC25BFNTAFNTB
SCHEMBL3405737 0.75 MAPK1 (0.59) TDP1CYP1A2GAAMAPTCDC25B
SCHEMBL6983909 0.74 RAB9A (0.56) CYP1A2GAAMAPTCDC25BALDH1A1
SCHEMBL3399414 0.74 KDM4E (0.41) ALDH1A1HSD17B10KDM4ELMNAKMT2A
SCHEMBL3402302 0.74 CDC25B (0.46) TDP1CYP1A2GAAMAPTCDC25B
SCHEMBL3404326 0.74 TLR8 (0.39) TDP1MAPTALDH1A1KDM4EKMT2A
SCHEMBL3402362 0.73 MAPK1 (0.51) TDP1GAAMAPTCDC25BFNTA
SCHEMBL3399820 0.73 HTR2C (0.44) ALDH1A1RAB9ASMN1; SMN2KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues LIGAND PHARMACEUTICALS, INC. (US) 2010-11-25 US disclosed
US-7728009-B1 Thiazole amides, imidazole amides and related analogues NEUROGEN CORPORATION (US) 2010-06-01 US disclosed
EP-1848428-A2 THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-10-31 EP disclosed
WO-2006089076-A9 THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES NEUROGEN CORP (US) 2007-04-26 WO disclosed
WO-2006089076-A2 THIAZOLE AMIDES, IMIDAZOLE AMIDES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2006-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297035-A1 Thiazole Amides, Imidazole Amides and Related Analogues HRH3, HRH4, HRH2 TDP1 2562/4885GABRA2 183/4885GABRB2 431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.